RecruitingRecruiting
Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
NCT06824818 · University of Chicago
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Feasibility Trial of LHRH Agonist Discontinuation in Elderly Prostate Cancer Patients
About this study
This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.
Eligibility criteria
Inclusion Criteria:
* Prostate cancer with \>3 years of LHRH agonist therapy.
* Age ≥70 years.
* ECOG performance status ≤2
* Baseline testosterone of \< 20 ng/ml
* No prior chemotherapy or Lu-PSMA (unless survival predictions are favorable).
* Ability to understand and sign informed consent.
Exclusion Criteria:
* none
Study design
Enrollment target: 155 participants
Allocation: na
Masking: none
Age groups: older_adult
Timeline
Starts: 2026-06
Estimated completion: 2027-06
Last updated: 2025-10-01
Interventions
Behavioral: LHRH Agonist Therapy Discontinuation
Primary outcomes
- • feasibility of stopping LHRH agonist therapy (12 months after discontinuing LHRH agonist therapy)
Sponsor
University of Chicago · other
Contacts & investigators
ContactClinical Trials Intake · contact · cancerclinicaltrials@bsd.uchicago.edu · 1-855-702-8222
InvestigatorNabiel Mir, MD · study_chair, University of Chicago
All locations (2)
The University of Illinois at Chicago (UIC)Recruiting
Chicago, Illinois, United States
UChicago Medicine Comprehensive Cancer CenterNot Yet Recruiting
Chicago, Illinois, United States